

In re Application of: SUZUKI ET AL.  
Confirmation No: 5129  
Application No.: 10/501,647  
Examiner: ZEMAN, Mary K.  
Page - 9 -

### REMARKS

Claims 16-28 were pending in the application at the time the Office Action was mailed. Claims 16-27 were rejected. Claim 28 was withdrawn as being directed to non-elected subject matter. Claims 16-27 were objected to for being misnumbered. Because the Office Action states that misnumbered claims 21-27 have been renumbered 22-28, Applicants understand that the examiner has renumbered these claims and that the objection is not outstanding. Claims 16-27 were rejected. No claims were allowed.

By this amendment, claims 16-22 and 24-27 have been amended. Claim 23 has been canceled. No claims have been added. Therefore, claims 16-22 and 24-28 remain pending in the application.

#### *Amendments to the Specification and Claims 17 and 20*

Paragraphs [0043] and [0076] of the specification and claims 17 and 20 have been amended herein to include the limitation "linkage disequilibrium." Support for "linkage disequilibrium" can be found in the application as filed in paragraphs [0043] and [0076] which recite "chain imbalance" and have been amended herein to instead recite "linkage disequilibrium." The present application is a US national phase application claiming priority to Japanese patent application numbers 2002-42355 and 2002-213695 which recite "rensa-fuheikou". The English translation of the Japanese applications translated "rensa-fuheikou" to "chain imbalance." However, Applicants submit that "linkage disequilibrium" is a more accurate translation of "rensa-fuheikou" and that amending the claims and specification to recite "linkage disequilibrium" does not constitute new matter. Attached hereto is a copy of three pages from a Japanese translation of Jurg Ott's textbook entitled "Analysis of Human Genetic Linkage" evidencing that "linkage disequilibrium" is translated as "rensa-fuheikou" in the Japanese language.

#### *Claim Rejections Under 35 U.S.C. § 112*

Claims 1-27 were rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 1-15 were previously canceled. Misnumbered claims 16-27 have been renumbered 16-28 and claim 28 has been withdrawn. Claim 23 has been canceled. Claims 16-22

In re Application of: SUZUKI ET AL.  
Confirmation No: 5129  
Application No.: 10/501,647  
Examiner: ZEMAN, Mary K.  
Page - 10 -

and 24-27 have been amended herein to address each rejection under 35 U.S.C. 112, second paragraph.

Accordingly, withdrawal of these rejections is respectfully requested.

***Claim Rejections Under 35 U.S.C. § 101***

Claims 16-27 were rejected under 35 U.S.C. 101 because the claimed invention is directed to non-statutory subject matter. According to the Office Action:

The claims are directed to methods of "specifying" SNP information that may be related to disease susceptibility or drug responsiveness. The claims do not recite statutory methods under 35 USC 101. The recited claims do not set forth any transformation of matter, nor do they provide a concrete, tangible and useful result. The result of claim 16 is a "target SNP" which is merely a piece of sequence information/data which differs in a single aspect from an unspecified reference. The SNP data is not linked to any particular disease susceptibility or drug response. The SNP information is not tangible or output to any user. The SNP data requires further interpretation or manipulation to be used or understood. The method does not produce a concrete result, as there is no assurance that any SNP will be found to be linked in any particular domain to the desired trait.

As amended herein, claim 16 (from which claims 17-22 and 24-27 depend) recites: "A method of identifying a single nucleotide polymorphism (SNP) that causes disease susceptibility or responsiveness to a drug comprising: obtaining data from a case group and data from a control group; defining a scanning domain for a gene thought to cause disease susceptibility or responsiveness to a drug or defining a scanning domain in a genomic region or in one or more chromosomes thought to cause disease susceptibility or responsiveness to a drug; selecting SNPs to obtain data by SNP haplotyping analysis in the scanning domain; defining a base sequence domain that contains a specified number of SNPs determined by a range of several SNPs to several hundred SNPs as a window, and shortening the physical distance of the scanning domain

In re Application of: SUZUKI ET AL.  
Confirmation No: 5129  
Application No.: 10/501,647  
Examiner: ZEMAN, Mary K.  
Page - 11 -

by estimating the base sequence domain near a target SNP that causes susceptibility to a disease or responsiveness to a drug by using the data of the selected SNPs; identifying said target SNP in the shortened scanning domain; and correlating the target SNP with responsiveness to a drug or with susceptibility to a disease."

Applicants submit that the claims as amended herein do result in a useful, concrete and tangible result, i.e., identifying an SNP that causes disease susceptibility or responsiveness to a drug. Thus, the claims as currently amended constitute statutory subject matter under §101.

Withdrawal of this rejection is therefore respectfully requested.

### *Claim Rejections Under 35 U.S.C. § 102*

Claims 16-27 were rejected under 35 U.S.C. 102(e) as being anticipated by Margus (U.S. patent no. 6,955,883). According to the Office Action:

Margus et al. (US 6,955,883 having priority to 3/26/02) discloses life science business models which obtain genomic information from a variety of populations and individuals, define domains or stretches of DNA which may contain SNP's of interest, identify SNP's within the domains, and specify targets, The targets may be associated with drug responsiveness or disease susceptibility. Wet steps of SNP typing may be performed, and statistical analyses of the significance of the findings can be performed. As such, Margus anticipates the methods of the claims.

As amended herein, claim 16 (from which claims 17-22 and 24-27 depend) recites: "A method of identifying a single nucleotide polymorphism (SNP) that causes disease susceptibility or responsiveness to a drug comprising: obtaining data from a case group and data from a control group; defining a scanning domain for a gene thought to cause disease susceptibility or responsiveness to a drug or defining a scanning domain in a genomic region or in one or more chromosomes thought to cause disease susceptibility or responsiveness to a drug; selecting SNPs

to obtain data by SNP haplotyping analysis in the scanning domain; defining a base sequence domain that contains a specified number of SNPs determined by a range of several SNPs to several hundred SNPs as a window, and shortening the physical distance of the scanning domain by estimating the base sequence domain near a target SNP that causes susceptibility to a disease or responsiveness to a drug by using the data of the selected SNPs; identifying said target SNP in the shortened scanning domain; and correlating the target SNP with responsiveness to a drug or with susceptibility to a disease."

Unlike the claimed invention, which provides for identifying an SNP that causes disease susceptibility or responsiveness to a drug without the need for analyzing all SNPs over a very large region, Margus discloses methods that require analyzing all SNPs over more than 10,000,000 bases. Because Margus does not teach the limitations of "defining a scanning domain for a gene thought to cause disease susceptibility or responsiveness to a drug or defining a scanning domain in a genomic region or in one or more chromosomes thought to cause disease susceptibility or responsiveness to a drug;" and "selecting SNPs to obtain data by SNP haplotyping in the scanning domain," claims 16-22 and 24-27 are not anticipated by this reference.

Accordingly, withdrawal of this rejection is respectfully requested.

Claims 16-27 were rejected under 35 U.S.C. 102(e) as being anticipated by Ramnarayan et al. According to the Office Action:

Ramnarayan et al. (US 2003/0158672 having priority to 11/10/2000) discloses methods of using SNP information to generate 31) models of drug targets, These methods obtain genomic information for genes or proteins which are targets of a defined drug from *a variety* of populations and individuals, define domains or stretches of DNA within those sequences which may contain SNP's of interest, identify SNP's within the domains, and specify targets. The targets may be associated with drug responsiveness. Wet steps of SNP typing may be performed, and statistical analyses of the significance of the findings can be performed. As such, Ramnarayan anticipates the methods of the claims.

As amended herein, claim 16 (from which claims 17-22 and 24-27 depend) recites: "A method of identifying a single nucleotide polymorphism (SNP) that causes disease susceptibility or responsiveness to a drug comprising: obtaining data from a case group and data from a control group; defining a scanning domain for a gene thought to cause disease susceptibility or responsiveness to a drug or defining a scanning domain in a genomic region or in one or more chromosomes thought to cause disease susceptibility or responsiveness to a drug; selecting SNPs to obtain data by SNP haplotyping analysis in the scanning domain; defining a base sequence domain that contains a specified number of SNPs determined by a range of several SNPs to several hundred SNPs as a window, and shortening the physical distance of the scanning domain by estimating the base sequence domain near a target SNP that causes susceptibility to a disease or responsiveness to a drug by using the data of the selected SNPs; identifying said target SNP in the shortened scanning domain; and correlating the target SNP with responsiveness to a drug or with susceptibility to a disease."

Because Ramnarayan et al. does not teach the limitations of "identifying an SNP that causes disease susceptibility or responsiveness to a drug" or "correlating the target SNP with responsiveness to a drug or with susceptibility to a disease", claims 16-22 and 24-27 are not anticipated by this reference. Accordingly, withdrawal of this rejection is respectfully requested.

Claims 16-27 were rejected under 35 U.S.C. 102(a) as being anticipated by Xu (GLAXO WO 2002/20835). According to the Office Action:

Xu et al. (WO 2002/20835, published 3/14/02: PTO-1449) discloses methods of associating phenotypes with haplotypes. These methods obtain genomic information from a variety of populations and individuals, define domains or stretches of DNA which may contain SNP's of interest, identify SNP's within the domains, and specify targets. The targets may be associated with phenotypes such as drug responsiveness or disease susceptibility. Wet steps of SNP typing may be

performed, and statistical analyses of the significance of the findings can be performed. As such, Xu anticipates the methods of the claims.

As amended herein, claim 16 (from which claims 17-22 and 24-27 depend) recites: "A method of identifying a single nucleotide polymorphism (SNP) that causes disease susceptibility or responsiveness to a drug comprising: obtaining data from a case group and data from a control group; defining a scanning domain for a gene thought to cause disease susceptibility or responsiveness to a drug or defining a scanning domain in a genomic region or in one or more chromosomes thought to cause disease susceptibility or responsiveness to a drug; selecting SNPs to obtain data by SNP haplotyping analysis in the scanning domain; defining a base sequence domain that contains a specified number of SNPs determined by a range of several SNPs to several hundred SNPs as a window, and shortening the physical distance of the scanning domain by estimating the base sequence domain near a target SNP that causes susceptibility to a disease or responsiveness to a drug by using the data of the selected SNPs; identifying said target SNP in the shortened scanning domain; and correlating the target SNP with responsiveness to a drug or with susceptibility to a disease."

Because Xu does not teach the limitations of "identifying an SNP that causes disease susceptibility or responsiveness to a drug" or "correlating the target SNP with responsiveness to a drug or with susceptibility to a disease", claims 16-22 and 24-27 are not anticipated by this reference.

Accordingly, withdrawal of this rejection is respectfully requested.

### CONCLUSION

The currently pending claims before the examiner are supported throughout the specification and are patentable over the prior art. No new matter has been added. This application is now in full condition for allowance, and such action is respectfully requested.

In re Application of: SUZUKI ET AL.  
Confirmation No: 5129  
Application No.: 10/501,647  
Examiner: ZEMAN, Mary K.  
Page - 15 -

This Amendment is accompanied by a retroactive petition for a one month extension of time and the required fees. Although Applicant believes that no further extensions of time are required with submission of this paper, Applicant requests that this submission also be considered as a petition for any further extensions of time if necessary. The Commissioner for Patents and Trademarks is hereby authorized to charge the amount due for any extensions of time and any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees paid on the filing or during prosecution of this application to Deposit Account No. 50-0951.


The examiner is cordially invited to call the undersigned if clarification is needed on any matter within this Amendment, or if the examiner believes a telephone interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,

AKERMAN SENTERFITT

Date:

July 17, 2008

  
Amy A. Dobbelaere, Ph.D.  
Reg. No. 52,088

AKERMAN SENTERFITT

P.O. Box 3188

West Palm Beach, FL 33402-3188

Tel: 561-653-5000

Docket No. 3883.021

7/26

[Based on this book]

Analysis of Human Genetic Linkage Third Edition

by

JURG OTT

©1985,1991,1999 The Johns Hopkins University Press

All rights reserved. First edition 1985

Third edition 1999

through The Tuttle-Mori Agency, Inc. in Tokyo

8/26

監訳者紹介

五條堀 孝

1974年 九州大学理学部生物学科卒業。理学博士  
現在 国立遺伝学研究所 生命情報・DDBJ研究センター長  
総合研究大学院大学生命科学研究科 教授（兼任）  
独立行政法人産業技術総合研究所生物情報解析センター  
副センター長（兼任）  
主要著書 人間は生命を創れるか—進化学のあゆみと未来、丸善ライ  
ブラリー（1995年）；ゲノム情報を読む、共立出版（1997  
年）など

訳者紹介

安田 徳一

1958年 早稲田大学第一理工学部数学科卒業。Ph. D in Genetics  
放射線医学総合研究所、国立遺伝学研究所などを経て  
現在 独立行政法人産業技術総合研究所生物情報解析センター  
特別研究員  
主要著書 人のための遺伝学、裳華房（1994年）。主要訳書 基礎集  
団遺伝学、培風館（1989年）；人類遺伝学、朝倉書店  
（1989年）など

NDC491 230p 27cm



ヒトゲノムの連鎖分析—疾患遺伝子の探索

2002年3月20日 第1刷発行

訳者 安田徳一

発行者 野間佐和子

発行所 株式会社 講談社

〒112-8001 東京都文京区音羽2-12-21  
販売部 (03) 5395-3624  
業務部 (03) 5395-3615

編集 株式会社 講談社サイエンティフィク

代表 鈴木俊男

〒162-0814 東京都新宿区新小川町9-25 日商ビル  
編集部 (03) 3235-3701

印刷所 株式会社双文社印刷所・半七写真印刷工業株式会社

製本所 島田製本株式会社

啓丁本・乱丁本は、講談社営業部宛にお送り下さい。  
送料小社負担にてお取替えます。なお、この本の内容についてのお問い  
合わせは講談社サイエンティフィク編集部宛にお願いいたします。  
定価はカバーに表示してあります。

© Norikazu Yasuda, 2002

〔JCLIS〕 < (株) 日本著作出版権管理システム委託出版物 >

本書の無断複写は著作権法上での例外を除き禁じられています。複写さ  
れる場合は、その都度事前に (株) 日本著作出版権管理システム (電話  
03-3817-5670, FAX 03-3815-8199) の許諾を得てください。

Printed in Japan

ISBN 4-06-153670-2 (KS)

9/26

218 ● 索 引

不一致 (inconsistent)	3	ミニサテライト (minisatellite)	17
ブートストラップ (bootstrap)	114	ミニマックス検定 (minimax test)	152
有病率データ (prevalence data)	173	メンデル型疾患 (mendelian disease)	140
フェルセンスグインのマップ関数 (Felsenstein's map function)	10	メンデル形質 (mendelian trait)	146
不完全浸透 (incomplete penetrance)	35, 83, 84, 134	モートンの検定法 (Morton's test)	119
不完全なヘテロ接合性 (incomplete heterozygosity)	72	モザイク (mosaicism)	149
複合仮説 (composite hypothesis)	25, 26	モッド値 (mod score)	180
複合形質 (complex trait)	171	モデル設定の間違い (model misclassification)	138
複雑系 (complex system)	171	戻し交配 (backcross)	51
複雑な家系 (complex pedigree)	101	戻し交配 (backcross)	7
複数座位実行可能マップ関数 (multiple-feasible map function)	70	モルガンのマップ関数 (Morgan's map function)	9
複数の罹患者 (multiple affected sibling)	153	モンテカルロ法 (Monte Carlo method)	110
父性確率計算 (paternity calculation)	109		
父性指標 (paternity index)	110	や	
ふたごデータ (twin data)	173	有意水準 (significant level)	25
物理距離 (physical distance)	11	優性 (dominance)	3
負の干渉 (negative interference)	68	優性遺伝 (dominant inheritance)	140
ブラーグ・ウィリ 症候群 (Prader-Willi syndrome)	149	優性効果 (dominance effect)	173
プリオン (prion)	171, 172	尤度 (likelihood)	21, 22
フローチャート (flow diagram)	188	尤度比 (likelihood ratio)	22
文化の伝達 (cultural inheritance)	172	尤度比検定 (LR検定) (likelihood ratio test)	25
分泌型 (secretor blood group)	14, 151		
分離の歪み (segregation distortion)	149	5	
分離比分析 (segregation analysis)	88	ラオのマップ関数 (Rao's map function)	10
分類の間違い (misclassification)	133	ラムダ(λ)比 (lambda-ratio)	172
平均値の検定 (mean test)	153	リスク比 (risk ratio λ)	176
平均ロッド値 (average lod score)	113	乱数 (random number)	110, 113
ベイズの定理 (Bayes theorem)	28, 146	卵巣腫瘍 (ovarian teratoma)	45
併発指数 (coefficient of coincidence)	68	ランダー・グリーンアルゴリズム (Lander-Green algorithm)	33, 44
べき変換 (power transformation)	94	罹患者 (affected sibling)	152
ヘテロ接合 (heterozygous)	3	罹患者同胞対法 (affected sib pair method: ASP分析)	43, 151, 155
ヘテロ接合性 (heterozygosity)	15	リスク計算の手順 (scheme for calculating risk)	191
ヘミ接合 (hemizygous)	3	量的形質 (quantitative trait)	95
ペンローズの同胞対法 (Penrose's sib-pair method)	151	量的形質座位 (quantitative trait locus: QTL)	93, 171
包括的マップ (comprehensive map)	63	ルーセラン血液型 (Lutheran blood group)	14, 151
放射線雑種マップ (radiation hybrid map)	19, 81	ループ (loop)	100
ホルデンの可算式 (Haldane addition formula)	69	劣性 (recessive)	3
ホルデンのマップ関数 (Haldane's map function)	10	劣性遺伝 (recessive inheritance)	140
母性遺伝 (maternal mode of inheritance)	5	連鎖群 (Linkage group)	8
発端者 (proband)	146, 148	連鎖検定 (test for linkage)	37
ホモ接合 (homozygous)	3	連鎖情報 (information for linkage)	8
ホモ接合性マッピング (homozygosity mapping)	141	連鎖について有意な証拠 (significant evidence for linkage)	36
ポリジーン (polygene)	96	連鎖の事後確率 (posterior probability of linkage)	33, 37
ポリジーン閾値形質 (polygene threshold trait)	171, 172	連鎖の事前確率 (prior probability of linkage)	33
ホルマンズの三角形 (Holman's triangle)	152	連鎖の情報 (information for linkage)	35
		連鎖の逐次検定法 (sequential test for linkage)	38
ま		連鎖不平衡 (linkage disequilibrium) ←	4, 156, 157
マーチン・ベル症候群 (Martin-Bell syndrome)	177	連鎖不平衡存続検定 (TDT) (transmission disequilibrium test)	163
マッピングの方法 (method of mapping)	76		
マップ関数 (map function)	9	連鎖不平衡の検定 (testing for linkage disequilibrium)	159
マップ距離 (map distance)	6	連鎖不平衡マッピング (disequilibrium mapping)	160
マップ群展 (map expansion)	68	連鎖ユーティリティプログラム (linkage utility program)	107
マップ特異的多点ロッド値 (map specific multipoint lod score)	63	ロケーション値 (location score)	79, 119
マップの構築 (map construction)	78	ロジスティック分布 (logistic distribution)	90
マップの統合 (map integration)	80	ロッド値 (lod score)	21, 22, 32, 98
		ロッド値分析 (lod score analysis)	155